News

The data presented are from studies measuring the effectiveness of an orally administered avian flu vaccine designed by Vaxart scientists using the company’s proprietary modular platform. The Vaxart

Anders Lonner, CEO of Meda, said: “This product has the potential to become the first once-a-day nasal antihistamine in the US. Beside better tolerance with the new formulation

According to the company, the initial personalized medicine services facilitate improved diagnostic, prognostic and therapeutic decision making for rheumatologists treating patients with rheumatoid arthritis (RA). Avise PG is

The Phase II study compared safety and efficacy of oral and intravenous forms of PTK 0796 to Zyvox in the treatment of patients with complicated skin and skin

The trial, conducted in accordance with FDA requirements, was a controlled, randomized, double-blind, partial cross-over study that compared Kamada’s intravenous alpha-1 antitrypsin (AAT) with a comparator product. Approximately

The Phase III study of almost 4,000 people 65 years of age and older compared the high-dose influenza vaccine with the standard inactivated influenza vaccine formulated for the

When choosing a high-energy device, physicians often must make trade-offs among device size, battery longevity and features. According to the company, the Cognis cardiac resynchronization therapy defibrillator and

The multicenter, double-blind, randomized, placebo-controlled Phase I study was designed to assess the safety and immunogenicity – a patient’s ability to generate an immune response – of four

This Phase II randomized study enrolled 253 patients with postsurgical pain. Three doses of ARRY-797 (200mg, 400mg and 600mg) were compared to placebo and celecoxib (400mg). In the